Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis
Version of Record online: 7 JUN 2006
Journal of Thrombosis and Haemostasis
Volume 4, Issue 9, pages 2090–2091, September 2006
How to Cite
WITTKOWSKY, A. K. (2006), Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis. Journal of Thrombosis and Haemostasis, 4: 2090–2091. doi: 10.1111/j.1538-7836.2006.02073.x
- Issue online: 7 JUN 2006
- Version of Record online: 7 JUN 2006
- Received 29 May 2006, accepted 1 June 2006
- 1Randomized comparison of low-molecular-weight heparin vs. oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin vs. a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153., , , , , , , , , , .
- 3for the LITE Investigators. A randomised trial evaluating long-term low-molecular-weight heparin therapy for three months vs. intravenous heparin followed by warfarin sodium in patients with current cancer. J Thromb Haemost 2003; 1: P1373a (Abstract)., , ,
- 6National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Venous Thromboembolic Disease. Version 1, 2006. http://www.nccn.org/professionals/physician_gls/default.asp .